Effect of variation of impression material combinations, dual arch tray types, and sequence of pour on the accuracy of working dies: "An in vitro study"

Aims: To evaluate the accuracy of dies made from dual arch impressions using different sectional dual arch trays, combinations of elastomeric impression materials, and the sequence of pour of dies. Subjects and Methods: The dual arch impression materials were grouped into three groups depending on the combination of impression materials used and each group is subdivided into four subgroups. A sample size of 8 in each subgroup yielding a total 96 impressions will be made into three groups of 32 each (Group I, II, and III). Group I constitute impressions made using monophase (M) impression material, Group II constitute impressions made using combination of heavy body and light body (HL), and Group III constitute impressions made using combination of putty and light body (PL). Dies obtained were evaluated with a travelling microscope to measure the buccolingual width of the tooth at the margin by using the sharp corners of the notches as reference points. Statistical Analysis Used: Descriptive analysis namely mean and standard deviation, one-way analysis of variance test. Results: The results obtained in this study indicate that though not statistically significant, the metal dual arch trays performed better when compared to the plastic trays in reproducing die dimensions. Conclusions: From the results obtained, dies poured from combination of heavy body and light body impressions using plastic or metal dual arch trays showed least variation in bucco-lingual dimension from master model

A simple energy efficient sol-gel combustion production of strontium orthosilicate and its biomedical study

Here we present a simple, effective, energy efficient method for the production of single phasic strontium orthosilicate (Sr2SiO4) powders at (1000 °C) low phase formation temperature using sol–gel combustion method. Detailed phase evaluation is investigated. The influence of different fuels on the synthesis of strontium orthosilicate also discussed. The prepared strontium orthosilicate powders were characterized using powder X-ray diffraction (XRD), Fourier transform infrared (FT-IR), Fourier transform Raman (FT-RAMAN), scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS) techniques. The strontium orthosilicate-polymer (chitin/chitosan) scaffold were prepared by solid state mixing. The strontium orthosilicate and strontium orthosilicate-polymer scaffold were found to have the ability to biomineralize as a bone substitute. The apatite formation ability was demonstrated by XRD studies after incubation up to 30 days. These preliminary in-vitro apatite formation abilities and hemocompatibility results show that strontium orthosilicate might possess properties that can serve as new biomedical material

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein

10.1371/journal.pntd.0006209PLoS Neglected Tropical Diseases122e000620

Phase 1 Trial of a Therapeutic Anti–Yellow Fever Virus Human Antibody

Copyright © 2020 Massachusetts Medical Society. BACKGROUND Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. METHODS In phase 1a of this clinical trial, we assessed the safety, side-effect profile, and pharmacokinetics of TY014, a fully human IgG1 anti–yellow fever virus monoclonal antibody. In a double-blind, phase 1b clinical trial, we assessed the efficacy of TY014, as compared with placebo, in abrogating viremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril). The primary safety outcomes were adverse events reported 1 hour after the infusion and throughout the trial. The primary efficacy outcome was the dose of TY014 at which 100% of the participants tested negative for viremia within 48 hours after infusion. RESULTS A total of 27 healthy participants were enrolled in phase 1a, and 10 participants in phase 1b. During phase 1a, TY014 dose escalation to a maximum of 20 mg per kilogram of body weight occurred in 22 participants. During phases 1a and 1b, adverse events within 1 hour after infusion occurred in 1 of 27 participants who received TY014 and in none of the 10 participants who received placebo. At least one adverse event occurred during the trial in 22 participants who received TY014 and in 8 who received placebo. The mean half-life of TY014 was approximately 12.8 days. At 48 hours after the infusion, none of the 5 participants who received the starting dose of TY014 of 2 mg per kilogram had detectable YF17D-204 viremia; these participants remained aviremic throughout the trial. Viremia was observed at 48 hours after the infusion in 2 of 5 participants who received placebo and at 72 hours in 2 more placebo recipients. Symptoms associated with yellow fever vaccine were less frequent in the TY014 group than in the placebo group. CONCLUSIONS This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein

<div><p>Dengue virus (DENV) infection imposes enormous health and economic burden worldwide with no approved treatment. Several small molecules, including lovastatin, celgosivir, balapiravir and chloroquine have been tested for potential anti-dengue activity in clinical trials; none of these have demonstrated a protective effect. Recently, based on identification and characterization of cross-serotype neutralizing antibodies, there is increasing attention on the potential for dengue immunotherapy. Here, we tested the ability of VIS513, an engineered cross-neutralizing humanized antibody targeting the DENV E protein domain III, to overcome antibody-enhanced infection and high but brief viremia, which are commonly encountered in dengue patients, in various <i>in vitro</i> and <i>in vivo</i> models. We observed that VIS513 efficiently neutralizes DENV at clinically relevant viral loads or in the presence of enhancing levels of DENV immune sera. Single therapeutic administration of VIS513 in mouse models of primary infection or lethal secondary antibody-enhanced infection, reduces DENV titers and protects from lethal infection. Finally, VIS513 administration does not readily lead to resistance, either in cell culture systems or in animal models of dengue infection. The findings suggest that rapid viral reduction during acute DENV infection with a monoclonal antibody is feasible.</p></div

PRNT₅₀ (ng/mL) values for anti-DENV antibodies.

<p>PRNT₅₀ (ng/mL) values for anti-DENV antibodies.</p